Screening period to be shortened over salt-modified medicines

The Health Insurance Review & Assessment Service said it will revise rules to shorten the screening period of salt- or dosage form-modified drugs to a period of 60-90 days, down from the current 150 days, in a move aimed at improving its national efficiency.

We can be able to simplify the evaluation process for these products as their mode of action is well define over newly developed medici...